{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:10:43Z","timestamp":1789002643086,"version":"build-2803163510"},"reference-count":0,"publisher":"International Union Against Tuberculosis and Lung Disease","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["int j tuberc lung dis"],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"<jats:p><jats:bold>BACKGROUND<\/jats:bold> Bronchiectasis is a common respiratory disease complicated by periodic exacerbations. The association with different degrees of gastric acid suppression has not been well studied.<jats:bold>METHODS<\/jats:bold> A retrospective cohort study of 350 patients was conducted to investigate\n the association of different gastric acid suppressants with bronchiectasis exacerbation that required hospitalisation. Components of FACED (FEV<jats:sub>1<\/jats:sub>% predicted, age, chronic colonisation by <jats:italic>Pseudomonas aeruginosa<\/jats:italic>, radiological extent of the disease, and dyspnoea) were adjusted\n in multivariate analysis.<jats:bold>RESULTS<\/jats:bold> Among patients with exacerbation of bronchiectasis, 52 (14.9%) required hospitalisation. Prescription of a high-dose of proton pump inhibitors (PPI) was associated with increased risk of bronchiectasis exacerbation requiring hospitalisation (adjusted\n OR 2.77, 95% CI 1.01\u20137.59; <jats:italic>P<\/jats:italic> = 0.05). There was no significant association with use of a histamine-2 receptor antagonist (H2RA) (OR 1.28, 95% CI 0.32\u20135.06) or low-dose PPI (OR 1.47, 95% CI 0.42\u20135.13). Nonetheless, patients prescribed a high dose of PPI required a significantly\n longer hospital stay for exacerbation (13.1 \u00b1 1.4 days) than patients not prescribed a gastric acid suppressant (8.2 \u00b1 2.6 days) or those on a low dose PPI (8.3 \u00b1 1.3 days) and H2RA (6.50 \u00b1 1.50 days).<jats:bold>CONCLUSIONS<\/jats:bold> Risk of bronchiectasis exacerbation requiring\n hospitalisation was increased among high-dose PPI users, but not those prescribed an H2RA or low-dose PPI.<\/jats:p>","DOI":"10.5588\/ijtld.22.0098","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T04:30:56Z","timestamp":1664253056000},"page":"917-921","source":"Crossref","is-referenced-by-count":3,"title":["High-dose proton pump inhibitors are associated with hospitalisation in bronchiectasis exacerbation"],"prefix":"10.5588","volume":"26","author":[{"given":"W. C.","family":"Kwok","sequence":"first","affiliation":[{"name":"Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. S.","family":"Cheung","sequence":"additional","affiliation":[{"name":"Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region, China, Department of Medicine, Shenzhen Hospital, The University of Hong Kong- Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. C. M.","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. F.","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Statistics, University of South Carolina, Columbia, SC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. K.","family":"Leung","sequence":"additional","affiliation":[{"name":"Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3554","container-title":["The International Journal of Tuberculosis and Lung Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/iuatld\/ijtld\/2022\/00000026\/00000010\/art00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T04:36:59Z","timestamp":1664944619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.5588\/ijtld.22.0098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":0,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,1]]}},"alternative-id":["1027-3719(20221001)26:10L.917;1-"],"URL":"https:\/\/doi.org\/10.5588\/ijtld.22.0098","relation":{},"ISSN":["1027-3719"],"issn-type":[{"value":"1027-3719","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,1]]}}}